Transcat, Inc. (NASDAQ: TRNS) is a Industrials company in the Industrial - Distribution industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | 129.42 | EPS (ttm) | 0.71 | Insider Own | 9.30% | Shs Outstand | 9.36M | Perf Week | 6.76% |
| Market Cap | 860.07M | Forward P/E | 42.89 | EPS next Y | 2.14 | Insider Trans | 0.00% | Shs Float | 9.12M | Perf Month | 0.19% |
| Enterprise Value | 984.07M | PEG | 5.92 | EPS next Q | - | Inst Own | - | Short Float | 5.65% | Perf Quarter | 30.21% |
| Income | 6.00M | P/S | 2.59 | EPS this Y | 147.89% | Inst Trans | - | Short Ratio | 3.08 | Perf Half Y | 45.72% |
| Sales | 332.00M | P/B | 2.86 | EPS next Y | 21.73% | ROA | 1.37% | Short Interest | 515.07K | Perf YTD | 61.98% |
| Book/sh | 32.16 | P/C | 172.01 | EPS next 5Y | 21.85% | ROE | 2.22% | 52W High | 95.22 -3.50% | Perf Year | 23.26% |
| Cash/sh | 0.53 | P/FCF | 40.92 | EPS past 3/5Y | -25.88% -11.16% | ROIC | 2.12% | 52W Low | 50.23 82.94% | Perf 3Y | 9.78% |
| Dividend Est. | - | EV/EBITDA | 24.60 | Sales past 3/5Y | 12.85% 13.92% | Gross Margin | 32.59% | Volatility | 5.63% 4.46% | Perf 5Y | 52.21% |
| Dividend TTM | - | EV/Sales | 2.96 | EPS Y/Y TTM | -54.78% | Oper. Margin | 4.14% | ATR (14) | 4.06 | Perf 10Y | 831.00% |
| Dividend Ex-Date | - | Quick Ratio | 1.99 | Sales Y/Y TTM | 19.42% | Profit Margin | 1.98% | RSI (14) | 58.27 | Recom | 2.20 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.33 | EPS Q/Q | 24.44% | SMA20 | 5.04% | Beta | 0.69 | Target Price | 123.60 |
| Payout | 0.00% | Debt/Eq | 0.43 | Sales Q/Q | 15.58% | SMA50 | 4.19% | Rel Volume | 0.75 | Prev Close | 89.58 |
| Employees | 1,413 | LT Debt/Eq | 0.43 | Earnings | Nov 02 | SMA200 | 25.23% | Avg Volume | 161.71K | Price | 91.89 |
| IPO Date | Dec 05, 1977 | Option/Short | Yes / Yes | EPS/Sales Surpr. | 0.45% -0.51% | Net Debt/EBITDA | 3.05 | Volume | 121,305 | Change | 2.58% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Oct-23-25 | Reiterated | Northland Securities | Market Perform | $110 → $95 |
| Jan-29-25 | Downgrade | Oppenheimer | Outperform → Perform | |
| Oct-30-24 | Reiterated | Northland Capital Markets | Market Perform | $100 → $110 |
| Oct-30-24 | Reiterated | Craig-Hallum | Buy | $138 → $113 |
| Oct-29-24 | Reiterated | HC Wainwright & Co. | Buy | $96 → $156 |
| Jul-31-24 | Reiterated | Craig-Hallum | Buy | $92 → $138 |
| May-22-24 | Reiterated | Oppenheimer | Outperform | $125 → $160 |
| Apr-18-24 | Reiterated | Oppenheimer | Outperform | $125 |
| Feb-02-23 | Reiterated | Roth Capital | Buy | $94 |
| Feb-01-23 | Reiterated | Craig-Hallum | Buy | $92 |
Transcat, Inc. offers comprehensive calibration and instrument services for laboratories, serving clients across the United States, Canada, and other international markets. The company operates through two distinct divisions: Service and Distribution. The Service division delivers a wide array of offerings, including precision calibration, equipment repair, thorough inspections, analytical qualification, preventive maintenance, and expert consulting. This segment also features its proprietary software, CalTrak, designed to manage documents and assets while streamlining the operational workflow for its calibration centers and customer equipment. Additionally, its "Compliance, Control and Cost" online portal grants customers web-based asset management capabilities and a secure, off-site repository for calibration and other service records. The Distribution division focuses on the sale and rental of instruments for testing, measurement, and control purposes. It also provides valuable supplementary services such as the calibration and certification of newly purchased equipment, equipment leasing, sales of pre-owned machinery, and customized equipment kitting. This division engages customers through its online platform, various digital and print marketing campaigns, proactive outbound sales efforts, and an incoming call center. Transcat primarily caters to highly regulated sectors, particularly the life sciences—encompassing pharmaceutical, biotechnology, medical device, and other FDA-regulated entities. Furthermore, it extends its services and products to aerospace and defense, industrial manufacturing, energy, utilities, and other industries where process accuracy and confirmed equipment performance are paramount. Established in 1964, Transcat, Inc. maintains its corporate headquarters in Rochester, New York.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2026 3/28/2026 | FY 2025 3/29/2025 | FY 2024 3/31/2024 | FY 2023 3/31/2023 | FY 2022 3/31/2022 | FY 2021 3/31/2021 | FY 2020 3/31/2020 | FY 2019 3/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 332 | 332 | 278 | 259 | 231 | 205 | 173 | 173 | 161 | |
| Cost of Goods Sold Incl. D&A | 225 | 224 | 189 | 176 | 162 | 147 | 127 | 131 | 122 | |
| Gross Profit | 108 | 108 | 89 | 84 | 68 | 58 | 46 | 42 | 39 | |
| Selling, General and Administrative Excl. Other | 95 | 95 | 72 | 64 | 52 | 44 | 35 | 32 | 29 | |
| Research and Development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Other Operating Expense | -1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Operating Income | 14 | 13 | 18 | 20 | 16 | 14 | 11 | 11 | 10 | |
| Interest Expense | 4 | 5 | 1 | 2 | 2 | 1 | 1 | 1 | 1 | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 1 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Net Income Before Taxes | 10 | 8 | 18 | 18 | 13 | 13 | 10 | 10 | 9 | |
| Income Taxes | 4 | 3 | 4 | 5 | 3 | 2 | 2 | 2 | 2 | |
| Consolidated Net Income | 6 | 5 | 15 | 14 | 11 | 11 | 8 | 8 | 7 | |
| Net Income From Continuing Operations | 6 | 5 | 15 | 14 | 11 | 11 | 8 | 8 | 7 | |
| Net Income | 6 | 5 | 15 | 14 | 11 | 11 | 8 | 8 | 7 | |
| EPS (Recurring) | 0.71 | 0.58 | 1.58 | 1.66 | 1.42 | 1.52 | 1.05 | 1.10 | 0.99 | |
| EPS (Basic, Before Extraordinaries) | 0.71 | 0.58 | 1.58 | 1.66 | 1.42 | 1.52 | 1.05 | 1.10 | 0.99 | |
| EPS (Diluted) | 0.71 | 0.57 | 1.57 | 1.63 | 1.40 | 1.50 | 1.03 | 1.08 | 0.95 | |
| EBITDA | 40 | 39 | 38 | 34 | 27 | 24 | 19 | 18 | 17 | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | 129.42 | 125.12 | 46.74 | 68.36 | 63.85 | 54.09 | 47.65 | 24.54 | 24.19 | |
| Price To Sales Ratio | 2.49 | 1.93 | 2.38 | 3.44 | 3.10 | 2.77 | 1.99 | 1.07 | 1.00 | |
| Gross Margin | 32.53 | 32.53 | 32.01 | 32.43 | 29.44 | 28.29 | 26.59 | 24.28 | 24.22 | |
| Operating Margin | 4.22 | 3.92 | 6.47 | 7.72 | 6.93 | 6.83 | 6.36 | 6.36 | 6.21 | |
| Net Margin | 1.81 | 1.51 | 5.40 | 5.41 | 4.76 | 5.37 | 4.62 | 4.62 | 4.35 | |
| Shares Outstanding | 9 | 9 | 9 | 8 | 8 | 7 | 7 | 7 | 7 | |
| Market Capitalization | 827 | 642 | 660 | 891 | 715 | 568 | 344 | 186 | 161 | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Rudow Lee D. | President and CEO | Mar 28 '26 | Option Exercise | 0.00 | 7,952 | 0 | 104,838 | Jun 11 |
| Rudow Lee D. | President and CEO | Mar 26 '26 | Option Exercise | 0.00 | 5,000 | 0 | 98,753 | Jun 11 |
| Barbato Thomas L | Sr. VP Finance & CFO | Mar 28 '26 | Option Exercise | 0.00 | 1,186 | 0 | 4,214 | Apr 01 |
| West Michael W. | Chief Operating Officer | Mar 28 '26 | Option Exercise | 0.00 | 725 | 0 | 26,823 | Apr 01 |
| Conroy Theresa A. | Sr. VP, Human Resources | Mar 28 '26 | Option Exercise | 0.00 | 524 | 0 | 2,163 | Apr 01 |
| Conroy Theresa A. | Sr. VP, Human Resources | Mar 26 '26 | Option Exercise | 0.00 | 1,500 | 0 | 2,382 | Apr 01 |
| West Michael W. | Chief Operating Officer | Mar 26 '26 | Option Exercise | 0.00 | 1,000 | 0 | 26,593 | Apr 01 |
| Barbato Thomas L | Sr. VP Finance & CFO | Mar 26 '26 | Option Exercise | 0.00 | 2,500 | 0 | 4,199 | Apr 01 |
| Mecca Robert | Director | Sep 11 '25 | Option Exercise | 0.00 | 704 | 0 | 704 | Sep 11 |
| Kaniki Mbago M. | Director | Sep 11 '25 | Option Exercise | 0.00 | 704 | 0 | 2,593 | Sep 11 |
| Haseley Gary J. | Director | Sep 11 '25 | Option Exercise | 0.00 | 704 | 0 | 39,102 | Sep 11 |
| Gillette Christopher P. | Director | Sep 11 '25 | Option Exercise | 0.00 | 704 | 0 | 704 | Sep 11 |
| DePerrior Dawn | Director | Sep 11 '25 | Option Exercise | 0.00 | 704 | 0 | 704 | Sep 11 |
| Dominach Oksana S. | Director | Sep 11 '25 | Option Exercise | 0.00 | 704 | 0 | 4,346 | Sep 11 |
| Cairns Craig D. | Director | Sep 11 '25 | Option Exercise | 0.00 | 704 | 0 | 5,003 | Sep 11 |